{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T14:24:06Z","timestamp":1788445446458,"version":"build-2803163510"},"reference-count":149,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Myelodysplastic syndromes are a group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, peripheral cytopenia, and dysplasia in one or more myeloid lineages, with a variable risk of progression to acute myeloid leukemia. In addition to well-characterized genetic and epigenetic abnormalities, oxidative stress has emerged as a critical contributor to the pathophysiology of myelodysplastic syndrome. Reactive oxygen species and reactive nitrogen species can induce cumulative DNA damage, mitochondrial dysfunction, and altered redox homeostasis, promoting genomic instability and clonal evolution. Elevated oxidative stress in patients with myelodysplastic syndromes has been linked to increased apoptosis of hematopoietic stem and progenitor cells, disruption of the bone marrow microenvironment, and progression toward leukemic transformation. Moreover, ROS-related pathways, such as TP53 mutations and epigenetic dysregulation, interact with the key molecular drivers of myelodysplastic syndrome. Given these findings, oxidative stress is now recognized not only as a hallmark of disease biology but also as a potential therapeutic target. Antioxidant-based strategies and agents that modulate redox signaling are being investigated for their ability to restore hematopoietic function and enhance treatment efficacy. This review provides an overview of the current biology of myelodysplastic syndrome, highlights the connections between oxidative stress and disease mechanisms, and explores emerging redox-targeted therapeutic approaches.<\/jats:p>","DOI":"10.3390\/ijms26136415","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T06:54:16Z","timestamp":1751525656000},"page":"6415","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Oxidative Stress and Mitochondrial Dysfunction in Myelodysplastic Syndrome: Roles in Development, Diagnosis, Prognosis, and Treatment"],"prefix":"10.3390","volume":"26","author":[{"given":"Federico","family":"Pierro","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Human Pathology in Adulthood and Childhood \u201cGaetano Barresi\u201d, University of Messina, Via Consolare Valeria, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8804-2640","authenticated-orcid":false,"given":"Manlio","family":"Fazio","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Human Pathology in Adulthood and Childhood \u201cGaetano Barresi\u201d, University of Messina, Via Consolare Valeria, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6403-6905","authenticated-orcid":false,"given":"Giuseppe","family":"Murdaca","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Genova, 16126 Genova, Italy"},{"name":"Allergology and Clinical Immunology, San Bartolomeo Hospital, 19038 Sarzana, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Stagno","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Human Pathology in Adulthood and Childhood \u201cGaetano Barresi\u201d, University of Messina, Via Consolare Valeria, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano","family":"Gangemi","sequence":"additional","affiliation":[{"name":"Allergy and Clinical Immunology Unit, Department of Clinical and Experimental Medicine, University of Messina, Via Consolare Valeria, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6156-8239","authenticated-orcid":false,"given":"Alessandro","family":"Allegra","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Human Pathology in Adulthood and Childhood \u201cGaetano Barresi\u201d, University of Messina, Via Consolare Valeria, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"key":"ref_1","first-page":"7","article-title":"The pathogenesis and classification of the myelodysplastic syndromes","volume":"75","author":"Jacobs","year":"1990","journal-title":"Br. J. Haematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/BF03165121","article-title":"Important features of myelodysplastic syndrome","volume":"76","author":"Hofmann","year":"2002","journal-title":"Int. J. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000489702","article-title":"Myelodysplastic Syndrome Updated","volume":"86","author":"Hasserjian","year":"2019","journal-title":"Pathobiology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1038\/s41375-022-01718-7","article-title":"Comparison of the revised 4th (2016) and 5th (2022) editions of the World Health Organization classification of myelodysplastic neoplasms","volume":"36","author":"Zhang","year":"2022","journal-title":"Leukemia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1182\/blood-2018-10-844670","article-title":"MDS overlap disorders and diagnostic boundaries","volume":"133","author":"Tanaka","year":"2019","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s10147-019-01462-6","article-title":"Genetic abnormalities and pathophysiology of MDS","volume":"24","author":"Hosono","year":"2019","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ejh.12515","article-title":"The molecular pathogenesis of the myelodysplastic syndromes","volume":"95","author":"Pellagatti","year":"2015","journal-title":"Eur. J. Haematol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Chiereghin, C., Travaglino, E., Zampini, M., Saba, E., Saitta, C., Riva, E., Bersanelli, M., and Della Porta, M.G. (2021). The Genetics of Myelodysplastic Syndromes: Clinical Relevance. Genes, 12.","DOI":"10.3390\/genes12081144"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000488712","article-title":"The Molecular Pathology of Myelodysplastic Syndrome","volume":"86","author":"Haferlach","year":"2019","journal-title":"Pathobiology"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Peng, X., Zhu, X., Di, T., Tang, F., Guo, X., Liu, Y., Bai, J., Li, Y., Li, L., and Zhang, L. (2022). The yin-yang of immunity: Immune dysregulation in myelodysplastic syndrome with different risk stratification. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.994053"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Glenth\u00f8j, A., \u00d8rskov, A.D., Hansen, J.W., Hadrup, S.R., O\u2019Connell, C., and Gr\u00f8nb\u00e6k, K. (2016). Immune Mechanisms in Myelodysplastic Syndrome. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17060944"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/BOR.0b013e32834db4ee","article-title":"Myelodysplasia and autoimmunity","volume":"24","author":"Giannouli","year":"2012","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1007\/s00277-018-3472-9","article-title":"Autoimmune manifestations associated with myelodysplastic syndromes","volume":"97","author":"Grignano","year":"2018","journal-title":"Ann. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised International Prognostic Scoring System for Myelodysplastic Syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"EVIDoa2200008","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular International Prognostic Scoring System for Myelodysplastic Syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/joim.12893","article-title":"Treatment of myelodysplastic syndrome in the era of next-generation sequencing","volume":"286","author":"Tobiasson","year":"2019","journal-title":"J. Intern. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/bjh.16206","article-title":"How we manage adults with myelodysplastic syndrome","volume":"189","author":"Fenaux","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1182\/hematology.2020000127","article-title":"Therapy for lower-risk MDS","volume":"2020","author":"Carraway","year":"2020","journal-title":"Hematology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jtct.2022.11.014","article-title":"Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome","volume":"29","author":"DeFilipp","year":"2023","journal-title":"Transplant. Cell. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"100791","DOI":"10.1016\/j.blre.2020.100791","article-title":"Current and emerging strategies for management of myelodysplastic syndromes","volume":"48","author":"Saygin","year":"2021","journal-title":"Blood Rev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa1908892","article-title":"Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes","volume":"382","author":"Fenaux","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJMoa061292","article-title":"Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion","volume":"355","author":"List","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1038\/s41375-018-0118-9","article-title":"A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-\u03b1 in anemic patients with low-risk MDS","volume":"32","author":"Fenaux","year":"2018","journal-title":"Leukemia"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1200\/JCO.20.02619","article-title":"Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes","volume":"39","author":"Santini","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","article-title":"Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission","volume":"383","author":"Wei","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1016\/j.clml.2021.09.009","article-title":"Injectable Hypomethylating Agents for Management of Myelodysplastic Syndromes: Patients\u2019 Perspectives on Treatment","volume":"22","author":"Zeidan","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"\u015eenel, P., Agar, S., Yurtsever, M., and G\u00f6lc\u00fc, A. (2024). Voltammetric quantification, spectroscopic, and DFT studies on the binding of the antineoplastic drug Azacitidine with DNA. J. Pharm. Biomed. Anal., 237.","DOI":"10.1016\/j.jpba.2023.115746"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Teodorescu, P., Pasca, S., Dima, D., Tomuleasa, C., and Ghiaur, G. (2020). Targeting the Microenvironment in MDS: The Final Frontier. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.01044"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s13287-020-01647-1","article-title":"Novel combinations to improve hematopoiesis in myelodysplastic syndrome","volume":"11","author":"Syed","year":"2020","journal-title":"Stem Cell Res. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Velegraki, M., Stiff, A., Papadaki, H.A., and Li, Z. (2022). Myeloid-Derived Suppressor Cells: New Insights into the Pathogenesis and Therapy of MDS. J. Clin. Med., 11.","DOI":"10.3390\/jcm11164908"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.molmed.2021.06.013","article-title":"Targeting low-risk myelodysplastic syndrome with novel therapeutic strategies","volume":"27","author":"Trivedi","year":"2021","journal-title":"Trends Mol. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/ajh.26397","article-title":"Roxadustat for the treatment of anemia in patients with LOWER-RISK myelodysplastic syndrome: Open-label, dose-selection, lead-in stage of a phase 3 study","volume":"97","author":"Henry","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1159\/000519568","article-title":"The Effect of Roxadustat on Transfusion-Dependent Myelodysplastic Syndrome Complicated by Chronic Kidney Disease","volume":"14","author":"Hara","year":"2021","journal-title":"Case Rep. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e70076","DOI":"10.1111\/cts.70076","article-title":"Imetelstat, a novel, first-in-class telomerase inhibitor: Mechanism of action, clinical, and translational science","volume":"17","author":"Lennox","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(23)01724-5","article-title":"Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): A multinational, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"403","author":"Platzbecker","year":"2024","journal-title":"Lancet"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Abaza, Y., and Zeidan, A.M. (2022). Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes. Cells, 11.","DOI":"10.3390\/cells11142249"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.22.01794","article-title":"Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study","volume":"41","author":"Sallman","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.biocel.2006.07.001","article-title":"Free radicals and antioxidants in normal physiological functions and human disease","volume":"39","author":"Valko","year":"2007","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4310469","DOI":"10.1155\/2017\/4310469","article-title":"Oxidative Stress in Disease and Aging: Mechanisms and Therapies Oxid","volume":"2017","author":"Simon","year":"2017","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"44879","DOI":"10.18632\/oncotarget.9821","article-title":"Mitochondrial dysfunction and oxidative stress in aging and cancer","volume":"7","author":"Kudryavtseva","year":"2016","journal-title":"Oncotarget"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Li, D., Yu, Q., Wu, R., Tuo, Z., Wang, J., Ye, L., Shao, F., Chaipanichkul, P., Yoo, K.H., and Wei, W. (2024). Interactions between oxidative stress and senescence in cancer: Mechanisms, therapeutic implications, and future perspectives. Redox Biol., 73.","DOI":"10.1016\/j.redox.2024.103208"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/cdd.2014.150","article-title":"Oxidative stress and autophagy: The clash between damage and metabolic needs","volume":"22","author":"Filomeni","year":"2015","journal-title":"Cell Death Differ."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3999083","DOI":"10.1155\/2022\/3999083","article-title":"Targeting Molecular Mediators of Ferroptosis and Oxidative Stress for Neurological Disorders","volume":"2022","author":"Li","year":"2022","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/ijc.34486","article-title":"Interplay of oncogenic signaling, oxidative stress, and ferroptosis in cancer","volume":"153","author":"Zeng","year":"2023","journal-title":"Int. J. Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/j.molcel.2021.02.033","article-title":"Loss of LUC7L2 and U1 snRNP subunits shifts energy metabolism from glycolysis to OXPHOS","volume":"81","author":"Jourdain","year":"2021","journal-title":"Mol. Cell"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"103308","DOI":"10.1016\/j.autrev.2023.103308","article-title":"Oxidative stress, mitochondrial dysfunction, and respiratory chain enzyme defects in inflammatory myopathies","volume":"22","author":"Danieli","year":"2023","journal-title":"Autoimmun. Rev."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10974-014-9380-2","article-title":"Oxidative stress in muscular dystrophy: From generic evidence to specific sources and targets","volume":"35","author":"Canton","year":"2014","journal-title":"J. Muscle Res. Cell Motil."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"8341286","DOI":"10.1155\/2017\/8341286","article-title":"Oxidative Stress in Liver Diseases: Pathogenesis, Prevention, and Therapeutics","volume":"2017","author":"Jadeja","year":"2017","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Zhang, C., Li, H., Li, J., Hu, J., Yang, K., and Tao, L. (2023). Oxidative stress: A common pathological state in a high-risk population for osteoporosis. Biomed. Pharmacother., 163.","DOI":"10.1016\/j.biopha.2023.114834"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"De Martinis, M., Allegra, A., Sirufo, M.M., Tonacci, A., Pioggia, G., Raggiunti, M., Ginaldi, L., and Gangemi, S. (2021). Vitamin D Deficiency, Osteoporosis and Effect on Autoimmune Diseases and Hematopoiesis: A Review. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22168855"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Senoner, T., and Dichtl, W. (2019). Oxidative Stress in Cardiovascular Diseases: Still a Therapeutic Target?. Nutrients, 11.","DOI":"10.3390\/nu11092090"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Yamada, Y., Takano, Y., Abe, J., Hibino, M., and Harashima, H. (2020). Therapeutic strategies for regulating mitochondrial oxidative stress. Biomolecules, 10.","DOI":"10.3390\/biom10010083"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Allegra, A., Pioggia, G., Tonacci, A., Musolino, C., and Gangemi, S. (2020). Oxidative Stress and Photodynamic Therapy of Skin Cancers: Mechanisms, Challenges and Promising Developments. Antioxidants, 9.","DOI":"10.3390\/antiox9050448"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/nrd4002","article-title":"Modulation of oxidative stress as an anticancer strategy","volume":"12","author":"Gorrini","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Allegra, A., Caserta, S., Genovese, S., Pioggia, G., and Gangemi, S. (2023). Gender differences in oxidative stress in relation to cancer susceptibility and survival. Antioxidants, 12.","DOI":"10.20944\/preprints202305.0677.v1"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4206","DOI":"10.1242\/dev.107086","article-title":"Stem cells and the impact of ROS signaling","volume":"141","author":"Bigarella","year":"2014","journal-title":"Development"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jcb.30506","article-title":"Predominant factors influencing reactive oxygen species in cancer stem cells","volume":"125","author":"Soundararajan","year":"2024","journal-title":"J. Cell. Biochem."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"5816","DOI":"10.1182\/blood-2011-01-326025","article-title":"Do reactive oxygen species play a role in myeloid leukemias?","volume":"117","author":"Hole","year":"2011","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s00011-012-0498-7","article-title":"Increase of novel biomarkers for oxidative stress in patients with plasma cell disorders and in multiple myeloma patients with bone lesions","volume":"61","author":"Gangemi","year":"2012","journal-title":"Inflamm. Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/09629350400008760","article-title":"Lipid peroxidation and protein oxidation in patients affected by Hodgkin\u2019s lymphoma","volume":"13","author":"Morabito","year":"2004","journal-title":"Mediat. Inflamm."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Xie, J.-B., Huang, S.-J., Yang, T.-B., Wang, W., Chen, B.-Y., and Guo, L. (2024). Comparison of machine learning methods for Predicting 3-Year survival in elderly esophageal squamous cancer patients based on oxidative stress. BMC Cancer, 24.","DOI":"10.1186\/s12885-024-13115-7"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1177\/1535370220920558","article-title":"Role of the mitochondrial stress response in human cancer progression","volume":"245","author":"Wang","year":"2020","journal-title":"Exp. Biol. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1016\/j.molcel.2022.07.012","article-title":"Stressed to death: Mitochondrial stress responses connect respiration and apoptosis in cancer","volume":"82","author":"Winter","year":"2022","journal-title":"Mol. Cell"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Luo, Y., Ma, J., and Lu, W. (2020). The significance of mitochondrial dysfunction in cancer. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21165598"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.exphem.2016.04.012","article-title":"Oxidative stress and hypoxia in normal and leukemic stem cells","volume":"44","author":"Testa","year":"2016","journal-title":"Exp. Hematol."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Kocabas, F., Xie, L., Xie, J., Yu, Z., DeBerardinis, R.J., Kimura, W., Thet, S., Elshamy, A.F., Abouellail, H., and Muralidhar, S. (2015). Hypoxic metabolism in human hematopoietic stem cells. Cell Biosci., 5.","DOI":"10.1186\/s13578-015-0020-3"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"108723","DOI":"10.1016\/j.celrep.2021.108723","article-title":"An IDH1-vitamin C crosstalk drives human erythroid development by inhibiting pro-oxidant mitochondrial metabolism","volume":"34","author":"Romano","year":"2021","journal-title":"Cell Rep."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Ivanov, S., Nano, O., Hana, C., Bonano-Rios, A., and Hussein, A. (2024). Molecular Targeting of the Isocitrate Dehydrogenase Pathway and the Implications for Cancer Therapy. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25137337"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.cell.2012.01.021","article-title":"Hypoxia-inducible factors in physiology and medicine","volume":"148","author":"Semenza","year":"2012","journal-title":"Cell"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1126\/science.1059796","article-title":"Targeting of HIF-\u03b1 to the von Hippel\u2013Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation","volume":"292","author":"Jaakkola","year":"2001","journal-title":"Science"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.molcel.2008.04.009","article-title":"Oxygen sensing by metazoans: The central role of the HIF hydroxylase pathway","volume":"30","author":"Kaelin","year":"2008","journal-title":"Mol. Cell"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Deynoux, M., Sunter, N., H\u00e9rault, O., and Mazurier, F. (2016). Hypoxia and hypoxia-inducible factors in leukemias. Front. Oncol., 6.","DOI":"10.3389\/fonc.2016.00041"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Magliulo, D., and Bernardi, R. (2022). Hypoxic stress and hypoxia-inducible factors in leukemias. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.973978"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Stergiou, I.E., Kambas, K., Poulaki, A., Giannouli, S., Katsila, T., Dimitrakopoulou, A., Vidali, V., Mouchtouris, V., Kloukina, I., and Xingi, E. (2021). Exploiting the role of hypoxia-inducible factor 1 and pseudohypoxia in the myelodysplastic syndrome pathophysiology. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22084099"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2217\/ijh.13.32","article-title":"Targeting hypoxia in the leukemia microenvironment","volume":"2","author":"Benito","year":"2013","journal-title":"Int. J. Hematol. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1158\/2159-8290.CD-18-1061","article-title":"Inhibition of HIF1\u03b1 signaling: A grand slam for MDS therapy?","volume":"8","author":"Chen","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1177\/147323001103900539","article-title":"Oxidative Stress Levels in Myelodysplastic Syndrome Patients: Their Relationship to Serum Ferritin and Haemoglobin Values","volume":"39","author":"Saigo","year":"2011","journal-title":"J. Int. Med. Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/BF02982641","article-title":"Oxidative Stress and the Myelodysplastic Syndromes","volume":"77","author":"Farquhar","year":"2003","journal-title":"Int. J. Hematol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.leukres.2013.07.008","article-title":"Oxidative stress leads to increased mutation frequency in a murine model of myelodysplastic syndrome","volume":"38","author":"Chung","year":"2014","journal-title":"Leuk. Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.3109\/10715762.2015.1035268","article-title":"Oxidative stress and mitochondrial dysfunction play a role in myelodysplastic syndrome development, diagnosis, and prognosis: A pilot study","volume":"49","author":"Oliveiros","year":"2015","journal-title":"Free. Radic. Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.leukres.2008.07.005","article-title":"Oxidative DNA damage in bone marrow cells of patients with low-risk myelodysplastic syndrome","volume":"33","author":"Novotna","year":"2009","journal-title":"Leuk. Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1600-0609.2007.00972.x","article-title":"Oxidative stress in red blood cells, platelets and polymorphonuclear leukocytes from patients with myelodysplastic syndrome","volume":"79","author":"Ghoti","year":"2007","journal-title":"Eur. J. Haematol."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Jing, Q., Zhou, C., Zhang, J., Zhang, P., Wu, Y., Zhou, J., Tong, X., Li, Y., Du, J., and Wang, Y. (2024). Role of reactive oxygen species in myelodysplastic syndromes. Cell. Mol. Biol. Lett., 29.","DOI":"10.1186\/s11658-024-00570-0"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1182\/blood-2008-12-195883","article-title":"Differential expression of NADPH oxidases in megakaryocytes and their role in polyploidy","volume":"114","author":"McCrann","year":"2009","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"R453","DOI":"10.1016\/j.cub.2014.03.034","article-title":"ROS Function in Redox Signaling and Oxidative Stress","volume":"24","author":"Schieber","year":"2014","journal-title":"Curr. Biol."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Hammad, M., Raftari, M., Ces\u00e1rio, R., Salma, R., Godoy, P., Emami, S.N., and Haghdoost, S. (2023). Roles of Oxidative Stress and Nrf2 Signaling in Pathogenic and Non-Pathogenic Cells: A Possible General Mechanism of Resistance to Therapy. Antioxidants, 12.","DOI":"10.3390\/antiox12071371"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1146\/annurev-pharmtox-010818-021856","article-title":"Modulating NRF2 in Disease: Timing Is Everything","volume":"59","author":"Dodson","year":"2019","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Zhao, Y., Ye, X., Xiong, Z., Ihsan, A., Ares, I., Mart\u00ednez, M., Lopez-Torres, B., Mart\u00ednez-Larra\u00f1aga, M.-R., Anad\u00f3n, A., and Wang, X. (2023). Cancer Metabolism: The Role of ROS in DNA Damage and Induction of Apoptosis in Cancer Cells. Metabolites, 13.","DOI":"10.3390\/metabo13070796"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Boura-Theodorou, A., Psatha, K., Maniatsi, S., Kourti, A., Kaiafa, G., Aivaliotis, M., and Makedou, K. (2025). Oxidative Stress and Its Role in the Emergence and Progression of Myelodysplastic Syndromes: Insights from Proteomic Analysis and Other Methodologies. Proteomes, 13.","DOI":"10.3390\/proteomes13020021"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.cell.2017.09.021","article-title":"Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease","volume":"171","author":"Stockwell","year":"2017","journal-title":"Cell"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nature23007","article-title":"Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway","volume":"547","author":"Viswanathan","year":"2017","journal-title":"Nature"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2013-04-491944","article-title":"Overproduction of NOX-derived ROS in AML promotes proliferation and is associated with defective oxidative stress signaling","volume":"122","author":"Hole","year":"2013","journal-title":"Blood"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrd2803","article-title":"Targeting cancer cells by ROS-mediated mechanisms: A radical therapeutic approach?","volume":"8","author":"Trachootham","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Nemeth, E., and Ganz, T. (2021). Hepcidin-Ferroportin Interaction Controls Systemic Iron Homeostasis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22126493"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.tips.2021.05.001","article-title":"Iron metabolism: Pathophysiology and pharmacology","volume":"42","author":"Roemhild","year":"2021","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"S\u0142omka, A., Pokrzywa, A., Strza\u0142a, D., Kubiaczyk, M., Wesolowska, O., Denkiewicz, K., and Styczy\u0144ski, J. (2024). The Role of Hepcidin in Myelodysplastic Syndromes (MDS): A Systematic Review of Observational Studies. Cancers, 16.","DOI":"10.3390\/cancers16020332"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e296","DOI":"10.1016\/j.lpm.2017.10.007","article-title":"Iron overload in hematological disorders","volume":"46","author":"Fibach","year":"2017","journal-title":"Presse M\u00e9d."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00277-010-1091-1","article-title":"Iron overload in MDS\u2014Pathophysiology, diagnosis, and complications","volume":"90","author":"Gattermann","year":"2011","journal-title":"Ann. Hematol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/ejh.13935","article-title":"Iron chelation therapy","volume":"110","author":"Bruzzese","year":"2023","journal-title":"Eur. J. Haematol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.leukres.2018.09.005","article-title":"Iron overload in myelodysplastic syndromes: Evidence based guidelines from the Canadian consortium on MDS","volume":"74","author":"Leitch","year":"2018","journal-title":"Leuk. Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1182\/hematology.2024000569","article-title":"Iron overload in acquired sideroblastic anemias and MDS: Pathophysiology and role of chelation and luspatercept","volume":"2024","author":"Gattermann","year":"2024","journal-title":"Hematology"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10238-019-00592-5","article-title":"Iron chelation therapy for myelodysplastic syndrome: A systematic review and meta-analysis","volume":"20","author":"Liu","year":"2020","journal-title":"Clin. Exp. Med."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez-Garc\u00eda, A., Morales, M.L., Garrido-Garc\u00eda, V., Garc\u00eda-Baquero, I., Leivas, A., Carre\u00f1o-Tarragona, G., S\u00e1nchez, R., Arenas, A., Cedena, T., and Ayala, R.M. (2019). Protein Carbonylation in Patients with Myelodysplastic Syndrome: An Opportunity for Deferasirox Therapy. Antioxidants, 8.","DOI":"10.3390\/antiox8110508"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.beha.2013.09.009","article-title":"When is iron overload deleterious, and when and how should iron chelation therapy be administered in myelodysplastic syndromes?","volume":"26","author":"Steensma","year":"2013","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"103367","DOI":"10.1016\/j.critrevonc.2021.103367","article-title":"Iron overload-induced oxidative stress in myelodysplastic syndromes and its cellular sequelae","volume":"163","author":"Kim","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1159\/000535749","article-title":"The Effect of Oral Iron Chelator Deferiprone on Iron Overload and Oxidative Stress in Patients with Myelodysplastic Syndromes: A Study by the Israeli MDS Working Group","volume":"147","author":"Merkel","year":"2024","journal-title":"Acta Haematol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"15400","DOI":"10.1096\/fj.202000933RR","article-title":"Phospholipase C beta1 (PI-PLC\u03b21)\/Cyclin D3\/protein kinase C (PKC) alpha signaling modulation during iron-induced oxidative stress in myelodysplastic syndromes (MDS)","volume":"34","author":"Cappellini","year":"2020","journal-title":"FASEB J."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.blre.2017.08.005","article-title":"A storm in the niche: Iron, oxidative stress and haemopoiesis","volume":"32","author":"Pilo","year":"2018","journal-title":"Blood Rev."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.clinbiochem.2017.05.018","article-title":"Oxidative imbalance in low\/intermediate-1-risk myelodysplastic syndrome patients: The influence of iron overload","volume":"50","author":"Ivars","year":"2017","journal-title":"Clin. Biochem."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","article-title":"Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death","volume":"149","author":"Dixon","year":"2012","journal-title":"Cell"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Zhang, J., Liu, Y., Li, Q., Xu, A., Hu, Y., and Sun, C. (2022). Ferroptosis in hematological malignancies and its potential network with abnormal tumor metabolism. Biomed. Pharmacother., 148.","DOI":"10.1016\/j.biopha.2022.112747"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/lifemeta\/loac035","article-title":"Mitochondria as multifaceted regulators of ferroptosis","volume":"1","author":"Guo","year":"2022","journal-title":"Life Metab."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1111\/cas.15810","article-title":"Mitochondrial dynamics as a pathobiological mediator of clonal myeloid disorders","volume":"114","author":"Hayashi","year":"2023","journal-title":"Cancer Sci."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Alberghina, L. (2023). The Warburg Effect Explained: Integration of Enhanced Glycolysis with Heterogeneous Mitochondria to Promote Cancer Cell Proliferation. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242115787"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"e740","DOI":"10.1097\/HS9.0000000000000740","article-title":"Metabolic Regulation of Hematopoietic Stem Cells","volume":"6","author":"Morganti","year":"2022","journal-title":"HemaSphere"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s13287-025-04304-7","article-title":"Mitochondrial quality control in hematopoietic stem cells: Mechanisms, implications, and therapeutic opportunities","volume":"16","author":"Liao","year":"2025","journal-title":"Stem Cell Res. Ther."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Guo, X., Can, C., Liu, W., Wei, Y., Yang, X., Liu, J., Jia, H., Jia, W., Wu, H., and Ma, D. (2023). Mitochondrial transfer in hematological malignancies. Biomark. Res., 11.","DOI":"10.1186\/s40364-023-00529-x"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"5472893","DOI":"10.1155\/2017\/5472893","article-title":"DNA methylation events as markers for diagnosis and management of acute myeloid leukemia and myelodysplastic syndrome","volume":"2017","author":"Dexheimer","year":"2017","journal-title":"Dis. Markers"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Gon\u00e7alves, A.C., Alves, R., Baldeiras, I., Marques, B., Oliveiros, B., Pereira, A., Costa, J.M.N., Cortes\u00e3o, E., Vieira, L.M., and Ribeiro, A.B.S. (2021). DNA Methylation Is Correlated with Oxidative Stress in Myelodysplastic Syndrome\u2014Relevance as Complementary Prognostic Biomarkers. Cancers, 13.","DOI":"10.3390\/cancers13133138"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s10238-015-0357-2","article-title":"Oxidative stress levels are correlated with P15 and P16 gene promoter methylation in myelodysplastic syndrome patients","volume":"16","author":"Oliveiros","year":"2016","journal-title":"Clin. Exp. Med."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1038\/leu.2017.229","article-title":"C\/EBP\u03b1 deregulation as a paradigm for leukemogenesis","volume":"31","author":"Pulikkan","year":"2017","journal-title":"Leukemia"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s12032-015-0605-z","article-title":"CEBPA methylation and mutation in myelodysplastic syndrome","volume":"32","author":"Wen","year":"2015","journal-title":"Med. Oncol."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Petzer, V., Theurl, I., Weiss, G., and Wolf, D. (2021). EnvIRONmental Aspects in Myelodysplastic Syndrome. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22105202"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/s41467-023-36193-w","article-title":"Myelodysplastic syndrome associated TET2 mutations affect NK cell function and genome methylation","volume":"14","author":"Boy","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Harris, B., Singh, D.K., Verma, M., Fahl, S.P., Rhodes, M., Sprinkle, S.R., Wang, M., Zhang, Y., Perrigoue, J., and Kessel, R. (2023). Ribosomal protein control of hematopoietic stem cell transformation through direct, non-canonical regulation of metabolism. bioRxiv.","DOI":"10.1101\/2023.05.31.543132"},{"key":"ref_128","first-page":"2520","article-title":"Arginine metabolism regulates human erythroid differentiation through hypusination of eIF5A","volume":"141","author":"Phadke","year":"2023","journal-title":"Blood"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1158\/1078-0432.CCR-13-1453","article-title":"Decitabine Induces Delayed Reactive Oxygen Species (ROS) Accumulation in Leukemia Cells and Induces the Expression of ROS Generating Enzymes","volume":"20","author":"Fandy","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3324\/haematol.2011.048231","article-title":"A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy","volume":"97","author":"Claus","year":"2012","journal-title":"Haematologica"},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Montes, P., Guerra-Librero, A., Garc\u00eda, P., Cornejo-Calvo, M.E., L\u00f3pez, M.d.S., de Haro, T., Mart\u00ednez-Ruiz, L., Escames, G., and Acu\u00f1a-Castroviejo, D. (2022). Effect of 5-Azacitidine Treatment on Redox Status and Inflammatory Condition in MDS Patients. Antioxidants, 11.","DOI":"10.3390\/antiox11010139"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/hon.2834","article-title":"Upregulated hypoxia inducible factor 1\u03b1 sig-naling pathway in high risk myelodysplastic syndrome and acute myeloid leukemia patients is associated with better response to 5-azacytidine\u2014Data from the Hellenic myelodysplastic syndrome study group","volume":"39","author":"Mpakou","year":"2021","journal-title":"Hematol. Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.semcancer.2017.11.001","article-title":"Vitamin C\u2014A new player in regulation of the cancer epigenome","volume":"51","author":"Gillberg","year":"2018","journal-title":"Semin. Cancer Biol."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Ottone, T., Faraoni, I., Fucci, G., Divona, M., Travaglini, S., De Bellis, E., Marchesi, F., Angelini, D.F., Palmieri, R., and Gurnari, C. (2022). Vitamin C Deficiency in Patients With Acute Myeloid Leukemia. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.890344"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.cell.2017.07.032","article-title":"Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression","volume":"170","author":"Cimmino","year":"2017","journal-title":"Cell"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.tiv.2013.03.009","article-title":"Oxidative stress mediates apoptotic effects of ascorbate and dehydroascorbate in human Myelodysplasia cells in vitro","volume":"27","author":"Alves","year":"2013","journal-title":"Toxicol. Vitr."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Kumar, S., Mathew, S.O., Aharwal, R.P., Tulli, H.S., Mohan, C.D., Sethi, G., Ahn, K.-S., Webber, K., Sandhu, S.S., and Bishayee, A. (2023). Withaferin A: A Pleiotropic Anticancer Agent from the Indian Medicinal Plant Withania somnifera (L.) Dunal. Pharmaceuticals, 16.","DOI":"10.3390\/ph16020160"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"77436","DOI":"10.18632\/oncotarget.20497","article-title":"Oxidative stress-induced JNK\/AP-1 signaling is a major pathway involved in selective apoptosis of myelodysplastic syndrome cells by Withaferin-A","volume":"8","author":"Oben","year":"2017","journal-title":"Oncotarget"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1111\/cas.12988","article-title":"Withaferin A suppresses the growth of myelodysplasia and leukemia cell lines by inhibiting cell cycle progression","volume":"107","author":"Okamoto","year":"2016","journal-title":"Cancer Sci."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.stem.2019.02.012","article-title":"The NAD-booster nicotinamide riboside potently stimulates hematopoiesis through increased mitochondrial clearance","volume":"24","author":"Vannini","year":"2019","journal-title":"Cell Stem Cell"},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Torello, C.O., Alvarez, M.C., and Saad, S.T.O. (2021). Polyphenolic flavonoid compound quercetin effects in the treatment of acute my-eloid leukemia and myelodysplastic syndromes. Molecules, 26.","DOI":"10.3390\/molecules26195781"},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Kim, Y., Kim, Y., Hwang, J., Van Den Broek, T.J., Oh, B., Kim, J.Y., Wopereis, S., Bouwman, J., and Kwon, O. (2021). A Machine Learning Algorithm for Quantitatively Diag-nosing Oxidative Stress Risks in Healthy Adult Individuals Based on Health Space Methodology: A Proof-of-Concept Study Using Korean Cross-Sectional Cohort Data. Antioxidants, 10.","DOI":"10.3390\/antiox10071132"},{"key":"ref_143","first-page":"16","article-title":"Artificial Intelligence (AI) to the Rescue: Deploying Machine Learning to Bridge the Biorelevance Gap in Antioxidant Assays","volume":"26","author":"Idowu","year":"2021","journal-title":"SLAS Technol. Transl. Life Sci. Innov."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"527","DOI":"10.4196\/kjpp.2024.28.6.527","article-title":"Predicting antioxidant activity of compounds based on chemical structure using machine learning methods","volume":"28","author":"Jung","year":"2024","journal-title":"Korean J. Physiol. Pharmacol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"20540","DOI":"10.1021\/acs.est.4c07390","article-title":"Comprehensive Characterization of Oxidative Stress-Modulating Chemicals Using GPT-Based Text Mining","volume":"58","author":"Liang","year":"2024","journal-title":"Environ. Sci. Technol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: Progress, challenges and recom-mendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1080\/17460441.2021.1883585","article-title":"Artificial intelligence, machine learning, and drug repurposing in cancer","volume":"16","author":"Tanoli","year":"2021","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.semcancer.2019.12.011","article-title":"Machine and deep learning approaches for cancer drug repurposing","volume":"68","author":"Issa","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"117164","DOI":"10.1016\/j.ejmech.2024.117164","article-title":"Advanced AI and ML frameworks for transforming drug discovery and opti-mization: With innovative insights in polypharmacology, drug repurposing, combination therapy and nanomedicine","volume":"284","author":"Ambreen","year":"2025","journal-title":"Eur. J. Med. Chem."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/13\/6415\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:03:50Z","timestamp":1760033030000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/13\/6415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":149,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["ijms26136415"],"URL":"https:\/\/doi.org\/10.3390\/ijms26136415","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,3]]}}}